A Phase II , Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)

Administered By

Awarded By

Contributors

Start/End

  • August 29, 2017 - December 31, 2020